Universe Pharmaceuticals (UPC) Receivables Refunds (2023 - 2025)
Universe Pharmaceuticals (UPC) has disclosed Receivables Refunds for 3 consecutive years, with $1.0 billion as the latest value for Q3 2025.
- Quarterly Receivables Refunds rose 115.24% to $1.0 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Sep 2025, up 115.24% year-over-year, with the annual reading at $1.0 billion for FY2025, 115.24% up from the prior year.
- Receivables Refunds hit $1.0 billion in Q3 2025 for Universe Pharmaceuticals, up from $475.3 million in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $1.0 billion in Q3 2025 to a low of $478899.0 in Q3 2023.
- Historically, Receivables Refunds has averaged $499.6 million across 3 years, with a median of $475.3 million in 2024.
- Biggest five-year swings in Receivables Refunds: soared 99154.96% in 2024 and later skyrocketed 115.24% in 2025.
- Year by year, Receivables Refunds stood at $478899.0 in 2023, then skyrocketed by 99154.96% to $475.3 million in 2024, then skyrocketed by 115.24% to $1.0 billion in 2025.
- Business Quant data shows Receivables Refunds for UPC at $1.0 billion in Q3 2025, $475.3 million in Q3 2024, and $478899.0 in Q3 2023.